Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.
SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.
CHICAGO -- Dapagliflozin (Farxiga) lowered mortality and heart failure worsening in high-risk older adults getting transcatheter aortic valve implantation (TAVI), the DapaTAVI trial showed. In a ...
Medicaid enrollees with type 2 diabetes (T2D) continue to face restricted access to newer cardioprotective diabetes medications — sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like ...
HOUSTON -- Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior reduction in albuminuria among chronic kidney disease patients at ...
Hyponatremia is the most common electrolyte disorder and a frequent trigger for urgent assessment in internal medicine. Beyond classic culprits such as thiazide diuretics and antidepressants, ...
A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results